Ausgabe 3/2016
Inhalt (23 Artikel)
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge
Daniel N. Cagney, Brian M. Alexander, F. Stephen Hodi, Elizabeth I. Buchbinder, Patrick A. Ott, Ayal A. Aizer
SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis)
Chanida Vinayanuwattikun, Siyamol Mingmalairak, Nutchawan Jittapiromsak, Iyavut Thaipisuttikul, Virote Sriuranpong, Apiwat Mutirangura, Shanop Shuangshoti
Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role
Elia Guadagno, Marialaura Del Basso De Caro, Sara Pignatiello, Concetta Sciammarella, Domenico Solari, Paolo Cappabianca, Francesco Maiuri, Flavia Dones
Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors
Irena Srebotnik-Kirbiš, Clara Limbäck-Stokin
Mir-449a, a potential diagnostic biomarker for WNT group of medulloblastoma
Yongxiao Li, Tao Jiang, Liwei Shao, Yan Liu, Chen Zheng, Yanfeng Zhong, Jing Zhang, Qing Chang
The effects of sequential treatments on hippocampal volumes in malignant glioma patients
Shantell C. Nolen, Brian Lee, Shruti Shantharam, Hon J. Yu, Lydia Su, John Billimek, Daniela A. Bota
A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study
Ralph Salloum, Trent R. Hummel, Shiva Senthil Kumar, Kathleen Dorris, Shaoyu Li, Tong Lin, Vinay M. Daryani, Clinton F. Stewart, Lili Miles, Tina Young Poussaint, Charles Stevenson, Stewart Goldman, Girish Dhall, Roger Packer, Paul Fisher, Ian F. Pollack, Maryam Fouladi, James Boyett, Rachid Drissi
Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors
Deborah T. Blumenthal, Michal Yalon, Gilad W. Vainer, Alexander Lossos, Shlomit Yust, Lior Tzach, Emanuela Cagnano, Dror Limon, Felix Bokstein
Does the choice of antiepileptic drug affect survival in glioblastoma patients?
Kristin M. Knudsen-Baas, Anders Engeland, Nils Erik Gilhus, Anette M. Storstein, Jone F. Owe
The incidence and significance of multicentric noncontrast-enhancing lesions distant from a histologically-proven glioblastoma
Arian Lasocki, Frank Gaillard, Mark A. Tacey, Katharine J. Drummond, Stephen L. Stuckey
Age alone is not a predictor for survival in glioblastoma
Lucy Gately, Anna Collins, Michael Murphy, Anthony Dowling
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma
Shiao-Pei Weathers, Xiaosi Han, Diane D. Liu, Charles A. Conrad, Mark R. Gilbert, Monica E. Loghin, Barbara J. O’Brien, Marta Penas-Prado, Vinay K. Puduvalli, Ivo Tremont-Lukats, Rivka R. Colen, W. K. Alfred Yung, John F. de Groot
The clinical significance of fascin expression in a newly diagnosed primary glioblastoma
Ki-Su Park, Hye Won Lee, Seong-Hyun Park, Tae In Park, Jeong-Hyun Hwang
Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion
Tomohiro Kawaguchi, Yukihiko Sonoda, Ichiyo Shibahara, Ryuta Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga
Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
Magnus Sabel, Gudrun Fleischhack, Stephan Tippelt, Göran Gustafsson, François Doz, Rolf Kortmann, Maura Massimino, Aurora Navajas, Katja von Hoff, Stefan Rutkowski, Monika Warmuth-Metz, Steven C. Clifford, Torsten Pietsch, Barry Pizer, Birgitta Lannering
Prognostic value of the S100B protein in newly diagnosed and recurrent glioma patients: a serial analysis
F. K. Holla, T. J. Postma, M. A. Blankenstein, T. J. M. van Mierlo, M. J. Vos, E. M. Sizoo, M. de Groot, B. M. J. Uitdehaag, J. Buter, M. Klein, J. C. Reijneveld, J. J. Heimans
Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma
Anne Hertenstein, Thomas Hielscher, Oliver Menn, Benedikt Wiestler, Frank Winkler, Michael Platten, Wolfgang Wick, Antje Wick
Utility of MRI versus tumor markers for post-treatment surveillance of marker-positive CNS germ cell tumors
Victoria Cheung, Devorah Segal, Sharon L. Gardner, David Zagzag, Jeffrey H. Wisoff, Jeffrey C. Allen, Matthias A. Karajannis
A cure is possible: a study of 10-year survivors of brain metastases
Rupesh Kotecha, Sally Vogel, John H. Suh, Gene H. Barnett, Erin S. Murphy, Chandana A. Reddy, Michael Parsons, Michael A. Vogelbaum, Lilyana Angelov, Alireza M. Mohammadi, Glen H. J. Stevens, David M. Peereboom, Manmeet S. Ahluwalia, Samuel T. Chao
Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy
Jacob Y. Shin, Aidnag Z. Diaz
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients
Jacob Y. Shin, Aidnag Z. Diaz
Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors
Francesca Duraturo, Raffaella Liccardo, Paola Izzo
Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg)
Chi Tung Choy, Chi Hang Wong, Herbert Ho Fung Loong